Repetitive transcranial magnetic stimulation is a non-invasive neuromodulation method that utilizes electromagnetic pulses to modulate neural activity in specific brain regions. Traditionally, rTMS has been most notably applied to treat conditions including major depressive disorder and obsessive-compulsive disorder. Its FDA approval for smoking cessation marks a significant extension into addiction therapy. However, challenges remain, such as the modest effectiveness across diverse patient populations and side effects like localized discomfort and headaches.

The research team, led by Dr. Xingbao Li, an associate professor within MUSC’s Department of Psychiatry and Behavioral Sciences, set out to enhance the precision and efficacy of rTMS by identifying neural markers predictive of individual treatment response. Using functional magnetic resonance imaging (fMRI), they captured resting-state and task-induced brain activity patterns from smokers exposed to cues such as images and videos associated with smoking behavior. This advanced neuroimaging technique measures changes in blood flow, serving as an indirect proxy for neuronal activity.

Central to their findings is the salience network, a major brain system responsible for filtering and prioritizing stimuli based on their behavioral relevance. While prior research predominantly focused on the reward network—governing motivation and pleasure—in nicotine addiction, this study reveals the salience network as a critical mechanistic bridge between rTMS modulation and successful smoking cessation. This insight challenges prevailing assumptions and opens new avenues for therapeutic targeting.

To analyze the high-dimensional and complex fMRI data, the team employed machine learning algorithms capable of detecting subtle and nonlinear patterns predictive of treatment outcomes. This approach overcomes conventional limitations by allowing computers to autonomously identify dysfunctional neural connectivity profiles without explicit programming rules. The result is a multivariate biomarker framework that can individualize rTMS treatment parameters.

Building upon an earlier MUSC clinical trial involving 42 adult smokers, where participants underwent either real or sham rTMS treatments paired with exposure to smoking-related stimuli, the current study leveraged retrospective imaging data. In that trial, real rTMS over the left dorsolateral prefrontal cortex was associated with significant reductions in daily cigarette consumption, cravings, and higher abstinence rates compared to the control group.

With the integration of fMRI and machine learning, the present study demonstrates that the connectivity strength within the salience network robustly predicts who benefits most from rTMS interventions. This predictive capability heralds a shift from uniform treatment protocols toward precision neuromodulation, where therapeutic strategies are tailored based on an individual’s neurobiological profile.

The implications of this research extend beyond nicotine addiction. The multimodal biomarker pipeline established here could be adapted for other substance use disorders, potentially transforming how neuropsychiatric conditions are managed. This personalized approach may reduce side effects by avoiding ineffective treatments and expedite recovery by focusing on neural circuits that critically govern addictive behavior.

Dr. Li emphasizes that the study paves the way for larger-scale investigations to validate and refine these findings. The success of such interdisciplinary efforts underscores the synergistic power of combining advanced neuroimaging, machine learning, and clinical neuroscience to tackle complex brain disorders.

Funding for this research was provided by the National Institutes of Health, and the team reported no conflicts of interest. Contributors include Kevin Caulfield, Ph.D., Andrew Chen, Ph.D., Christopher McMahan, Ph.D., Karen Hartwell, M.D., Kathleen Brady, M.D., Ph.D., and Mark George, M.D., all bringing expertise that spans psychiatry, neuroscience, and bioengineering.

By moving beyond static stimulation targets and embracing the heterogeneity of brain network dysfunctions in smokers, MUSC researchers exemplify how modern technology can catalyze the evolution of neurotherapeutic modalities. This study exemplifies a paradigm shift toward data-driven, individually optimized interventions, offering renewed hope to millions struggling with tobacco dependence worldwide.

Subject of Research: Neural Predictors of rTMS Efficacy in Smoking Cessation using Machine Learning and fMRI
Article Title: Salience Network Connectivity Predicts Response to Repetitive Transcranial Magnetic Stimulation in Smoking Cessation: A Preliminary Machine Learning Study
News Publication Date: 15-Sep-2025
Web References: http://dx.doi.org/10.1177/21580014251376722
References: Li, X., Caulfield, K., Chen, A., McMahan, C., Hartwell, K., Brady, K., George, M. (2025). Brain Connectivity.
Image Credits: Image courtesy of the MUSC research team
Keywords: Substance related disorders, Behavioral neuroscience

Throughout her 45-year tenure in behavioral pharmacology, Dr. de Wit’s methodological innovations have transformed our comprehension of drugs like MDMA and LSD. These substances, once relegated to counterculture notoriety, are now at the forefront of translational neuroscience research, thanks in large part to her work. Her approach seamlessly integrates animal behavioral studies with controlled human experiments, thereby clarifying the complex biological and psychological mechanisms these compounds engage. This cross-species research synthesis offers an unprecedented platform for developing novel therapeutic protocols rooted in empirical science rather than anecdotal evidence.

One of Dr. de Wit’s most striking contributions has been her elucidation of MDMA’s unique capacity to enhance social connectedness. Her experiments demonstrate that MDMA administration produces profound pro-social effects by modulating neural circuits associated with empathy and emotional processing. These findings are reshaping therapeutic strategies for post-traumatic stress disorder (PTSD) across continents, suggesting that psychoactive substances can facilitate emotional breakthroughs and healing where conventional treatments have struggled. The neuropharmacological bases of these effects implicate changes in serotonergic, oxytocinergic, and dopaminergic systems, which together underpin the drug’s capacity to amplify feelings of trust and safety during psychotherapy.

Delving deeper into the translational aspect of her work, Dr. de Wit highlights a compelling discovery in addiction neuroscience: human smokers, much like laboratory rats, exhibit paradoxically increased craving after prolonged abstinence. This counterintuitive pattern challenges prevailing models that assume craving diminishes with time away from the substance. The implications for rehabilitation protocols are profound, demanding a re-evaluation of relapse prevention frameworks globally. Her findings underscore a critical reevaluation of how we conceptualize withdrawal and craving dynamics, inviting a more nuanced approach that accounts for behavioral conditioning and neuroadaptive mechanisms conserved across species.

The last fifteen years of Dr. de Wit’s research have pivoted towards investigating the subjective psychological states induced by “mind-altering” substances, including low-dose psychedelics and entactogens. These studies uniquely tackle the challenge of assessing internal experiential phenomena—such as empathy, awe, and a sense of environmental oneness—that cannot be captured through traditional animal models. By employing rigorous psychometric tools combined with neuroimaging techniques, her laboratory has identified consistent patterns in how these drugs alter consciousness. These insights contribute to a growing neuroscientific framework that seeks to decode the neural correlates of complex emotional and existential experiences.

Her work provokes foundational questions about consciousness itself, bridging neuroscience, psychology, and philosophy. Do the empathetic and unitive feelings elicited by psychedelics reflect universal neural processes intrinsic to human cognition, or are they culturally modulated constructs? Dr. de Wit’s cross-cultural collaborations hint at the universality of these experiences, suggesting that consciousness-altering compounds reveal shared human dimensions that transcend national and ethnic boundaries. This perspective fuels a compelling narrative where science illuminates the common threads weaving diverse human experiences together.

Dr. de Wit’s journey began in Ottawa and was shaped by formative stints at Oxford University and Concordia University, training under renowned scientists like Jeffrey Gray and Jane Stewart. These international academic environments fostered her integrative vision of pharmacology and psychology. This rich mentorship and cross-disciplinary exposure empowered her to evolve innovative experimental paradigms that continue to influence laboratories globally—from Tokyo’s advanced neuroimaging centers to Berlin’s cutting-edge behavioral pharmacology institutes. Her global influence is further cemented through editorial leadership roles in high-impact journals, where she advocates for high standards and open scientific discourse.

A substantial portion of her recent research explores microdosing—the administration of sub-perceptual psychedelic doses—and its potential to induce neuroplasticity. Dr. de Wit’s investigations reveal that these low doses may subtly augment synaptic remodeling and cognitive flexibility, opening new avenues for enhancing mental health without overt psychoactive effects. These findings challenge traditional dose-response assumptions and open promising discussions about personalized medicine approaches in psychopharmacology. Her laboratory’s integration of molecular biology, behavioral assays, and subjective report analyses provides a comprehensive understanding of microdosing’s therapeutic potential.

Beyond her scientific accomplishments, Dr. de Wit embodies a personal philosophy grounded in patience, curiosity, and simplicity. She candidly shares how her perseverance in watercolor painting parallels the meticulous and incremental progress fundamental to scientific discovery. Her steadfast commitment to securing continuous NIH funding for over four decades is a testament to her unwavering dedication and excellence in research—a rarity in today’s competitive academic climate. She emphasizes simplicity in experiment design as pivotal for disentangling complex drug effects and generating reproducible data that can withstand global scientific scrutiny.

In this age marked by skepticism toward science, Dr. de Wit voices a crucial plea for revitalizing public education and societal respect for research. She underscores that sustainable scientific advancement hinges not only on brilliant individuals but equally on collective investment in education systems worldwide. This vision resonates deeply amid growing challenges faced by the scientific community, from funding constraints to misinformation. Her advocacy serves as a clarion call for renewed public engagement and policy support to nurture the next generation of researchers tackling some of humanity’s most pressing mental health crises.

Dr. de Wit’s interview also illuminates the importance of narrative in science communication. Psychedelics’ “Innovators & Ideas” series artfully blends technical insights with personal stories, providing a comprehensive portrayal of scientists as both rigorous investigators and relatable humans. This format enhances public understanding and enthusiasm for complex scientific topics by making them accessible without sacrificing depth. It exemplifies how thoughtful storytelling can inspire viral dissemination and broaden impact across scholarly and popular audiences alike.

As the field of psychedelic research rapidly evolves, Dr. de Wit remains a guiding beacon, challenging paradigms and expanding horizons. Her integrated approach—melding behavioral pharmacology with nuanced human experiential data—ushers a new era where psychoactive substances are not merely studied but thoughtfully harnessed for healing. Her visionary leadership continues to catalyze collaborations that span continents and disciplines, turning once fringe substances into frontline tools addressing global mental health challenges. The research she has championed promises to unlock deeper understanding of the human brain and the very nature of consciousness in the years to come.

Subject of Research: People

Article Title: Harriet de Wit: What can we learn about behavior and brain processes by studying psychoactive drugs in humans? How can we harmonize behavioral research in humans and nonhuman species?

News Publication Date: 26-Aug-2025

Web References:
https://doi.org/10.61373/pp025k.0029

Image Credits: Harriet de Wit